There have been dramatic therapeutic advances in MM—including the establishment of triplet and quadruplet regimens containing anti-CD38 monoclonal antibodies in newly diagnosed MM, bispecific T-cell engagers, and chimeric antigen receptor (CAR) T-cell therapies. The gene discussed is CD38; the disease is Miyoshi myopathy.